Transgenic expression of P1A induced thymic tumor: A role for onco-fetal antigens in tumorigenesis

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Li, Chi Shan ^a,c   Chen, Chong ^a   Zheng, Pan ^a,b   Liu, Yang ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOFETAL ANTIGEN; ONCOFETAL ANTIGEN P1A; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; LYMPHOID CELL; MOUSE; NONHUMAN; SURVIVAL RATE; SURVIVAL TIME; THYMOMA; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; CELL LINEAGE; CELL TRANSFORMATION; GENETICS; PHYSIOLOGY; TRANSGENIC ANIMAL;

MUS MUSCULUS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; MICE; THYMUS NEOPLASMS;

EID: 78149450869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013439     Document Type: Article

References (24)

1. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725-729.
2. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373-1384.
3. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157: 1040-1052.
4. Ramarathinam L, Sarma S, Maric M, Zhao M, Yang G, et al. (1995) Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 155: 5323-5329.
5. Uyttenhove C, Godfraind C, Lethe B, Amar-Costesec A, Renauld JC, et al. (1997) The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer 70: 349-356.
6. Sarma S, Guo Y, Guilloux Y, Lee C, Bai XF, et al. (1999) Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med 189: 811-820.
7. Sakaguchi N, Kashiwamura S, Kimoto M, Thalmann P, Melchers F (1988) B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties. Embo J 7: 3457-3464.
8. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
9. Rosenbaum H, Harris AW, Bath ML, McNeall J, Webb E, et al. (1990) An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. Embo J 9: 897-905.
10. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW (1989) N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. Embo J 8: 749-755.
11. Sun XH (1994) Constitutive expression of the Id1 gene impairs mouse B cell development. Cell 79: 893-900.
12. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, et al. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56: 673-682.
13. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. (1992) RAG-2- deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68: 855-867.
14. Van den Eynde B, Mazarguil H, Lethe B, Laval F, Gairin JE (1994) Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur J Immunol 24: 2740-2745.
15. Magliocca JF, Held IK, Odorico JS (2006) Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev 15: 707-717.
16. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.
17. Wu L, Antica M, Johnson GR, Scollay R, Shortman K (1991) Developmental potential of the earliest precursor cells from the adult mouse thymus. J Exp Med 174: 1617-1627.
18. Shortman K, Wu L (1996) Early T lymphocyte progenitors. Annu Rev Immunol 14: 29-47.
19. Kawamoto H, Ohmura K, Katsura Y (1998) Presence of progenitors restricted to T, B, or myeloid lineage, but absence of multipotent stem cells, in the murine fetal thymus. J Immunol 161: 3799-3802.
20. Penn I (1994) Depressed immunity and the development of cancer. Cancer Detect Prev 18: 241-252.
21. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
22. Hadden JW (2003) Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 3: 1061-1071.
23. Mueller BU, Pizzo PA (1995) Cancer in children with primary or secondary immunodeficiencies. J Pediatr 126: 1-10.
24. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.